Safety Analysis and Risk Management of Daprodustat

Daprodustat (Daprodustat) is a new oral hemoglobin stimulator (HIF-PHI), which stabilizes hypoxia-inducible factor (HIF) by inhibiting prolyl hydroxylase (PHDs), thereby inducing the synthesis of endogenous erythropoietin (EPO), thereby stimulating the production of red blood cells. This mechanism is different from traditional erythropoiesis-stimulating agents (ESA) treatments, which promote erythropoiesis through exogenous supplementation of erythropoietin. As a new generation drug, dapostat has demonstrated obvious advantages in terms of therapeutic effect, patient compliance and safety. Compared with traditional ESA treatment, it has unique clinical application value.

In the treatment of patients with chronic kidney disease-related anemia(CKD), ESA drugs have always been the first choice for routine treatment. They improve anemia symptoms by increasing hemoglobin levels and reduce the patient's need for blood transfusions. However, ESA treatment also has some limitations, such as the need to be administered by injection, the potential for cardiovascular adverse events (such as hypertension and thrombosis), and poor patient compliance. In contrast, dapostat, as an oral drug, is not inferior to ESA in terms of therapeutic effect, and even shows certain advantages in some aspects.

The mechanism of action of daporostat is not only by increasing the level of erythropoietin (EPO), but also by improving iron metabolism, promoting iron utilization, and ensuring the smooth progress of red blood cell production. Many clinical studies have shown that daplostat can effectively increase patients' hemoglobin levels, and in long-term treatment, daplostat can provide a more stable therapeutic effect than traditional ESA drugs. In addition, since dapostat is an oral drug, patients' compliance has been significantly improved and they do not have to rely on injections like ESA, thus improving patients' quality of life.

Daplostat also shows potential in reducing cardiovascular risk compared with ESA treatment. Although long-term use of ESA is associated with an increase in cardiovascular events, especially when hemoglobin is too high, which may have negative effects, daprostat has shown fewer cardiovascular adverse effects in clinical studies through its regulatory mechanism. At the same time, daprostat is also considered superior in reducing the risk of thromboembolic events.

Although dapostat has clinically demonstrated efficacy comparable to that of ESA, its unique oral administration method and fewer side effects make it a strong choice for patients with anemia in chronic kidney disease. According to some clinical trial results, daprostat is less likely to cause drug dependence or significant side effects during treatment, and therefore is better tolerated in long-term use. This also makes dapostat more suitable for patients who do not want to receive regular injections during treatment.

Reference materials:https://en.wikipedia.org/wiki/Daprodustat